Cat. No. 3389
No more than 1 g per individual per year to be sold without prior permission from the license holder.
Alternative Names: Casodex, ICI 176,334
Chemical Name: N-[4-Cyano-3-(trifluoromethyl)pheny
Biological ActivityOrally active non-steroidal androgen receptor antagonist (IC50 = 190 nM). Displays peripheral selectivity and does not effect serum levels of LH and testosterone. Exhibits potent anticancer activity in vivo.
Licensing InformationSold for research purposes only under agreement from AstraZeneca
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Furr and Tucker (1996) The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 47 13. PMID: 8560673.
Tucker et al (1988) Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J.Med.Chem. 31 954. PMID: 3361581.
Furr et al (1987) ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J.Endocrinol. 113 R7. PMID: 3625091.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Bicalutamide include:
Gambara et al (2015) TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. J Cell Mol Med 19 327. PMID: 25444175.
Ishizaki et al (2013) Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Sci Rep 3 1528. PMID: 23524847.
Do you know of a great paper that uses Bicalutamide from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Bicalutamide, supplier, Non-steroidal, Androgen, receptor, antagonists, Dihydrotestosterone, Receptors, AstraZeneca, ICI176,334, chemotherapeutics, Tocris Bioscience, Androgen Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonistIP7e
Potent Nurr1 activatorBexarotene
Potent and selective RXR agonistGSK 2033
Potent LXR antagonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.